Saliva provides an easy to collect sample type for SARS-CoV-2 diagnostic testing and screening, and it is utilized by numerous tests with FDA Emergency Use Authorization. Numerous saliva tests include a collection process that uses stabilizers and preservatives with a sample extraction step prior to molecular testing, but in recent months several tests have been developed to utilize minimally processed raw saliva followed by direct molecular detection. Co-Diagnostics, Inc. has conducted an investigation into the compatibility of its patented Co-Primers technology with detection of SARS-CoV-2 directly from raw saliva. We used various Co-Primers assay configurations to consistently detect SARSCoV-2 in minimally processed saliva with confirmed sensitivity limits as low as 347 copy/mL, and determined Co-Primers to be a robust platform for the development of such tests in the future.
Read the article here:
